Specific Use-Results Survey of TAKHZYRO Subcutaneous Injection 300 mg Syringe for Hereditary Angioedema With Long-term Administration
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Lanadelumab (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors Takeda
- 13 Mar 2025 Planned End Date changed from 31 Aug 2026 to 31 Jan 2026.
- 13 Mar 2025 Planned primary completion date changed from 31 Aug 2026 to 31 Jan 2026.
- 22 Jun 2022 Status changed from not yet recruiting to recruiting.